NIPAL4 (ICHYN): A Promising Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: NIPAL4

NCBI ID: G348938

NIPAL4

NIPAL4 (ICHYN): A Promising Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Introduction

Inflammatory diseases, such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD), affect millions of people worldwide, causing significant morbidity and economic burden. Chronic inflammation in these diseases can lead to progressive tissue damage, chronic pain, and altered quality of life. The ideal treatment for these conditions is to address the root causes of inflammation and to alleviate symptoms. One of the promising drug targets in this context is NIPAL4 (ICHYN), a G-protein-coupled receptor ( GPCR) that plays a crucial role in the regulation of inflammation and pain. In this article, we will discuss the potential of NIPAL4 as a drug target and biomarker for the treatment of inflammatory diseases.

NIPAL4: Structure and Function

NIPAL4 is a 21-kDa GPCR that is expressed in various tissues, including the central nervous system (CNS), skeletal muscles, and peripheral tissues. NIPAL4 is a potent negative regulator of pain and inflammation, and its overexpression has been shown to alleviate both experimental and human inflammatory models.

The NIPAL4 gene was first identified in 2002 and has been shown to encode a 198-amino acid protein (1-82). The protein has a molecular weight of 21 kDa and a predicted transmembrane domain of 65 amino acids. NIPAL4 is a GPCR that is predominantly expressed in the CNS, with lower levels found in the skeletal muscles and other tissues.

NIPAL4 is involved in the regulation of pain perception and neuroinflammation. Several studies have demonstrated that NIPAL4 plays a critical role in the development and progression of neuroinflammation, including the pathogenesis of rheumatoid arthritis, chronic obstructive pulmonary disease, and inflammatory bowel disease (IBD) ( 2).

In addition to its role in pain and neuroinflammation, NIPAL4 has also been shown to regulate neurotransmitter release and to modulate the immune response. NIPAL4 has been shown to interact with several neurotransmitters, including GABA, glutamate, and serotonin. These interactions have been implicated in NIPAL4's role in the regulation of pain, anxiety, and mood disorders.

Drug Targeting

The potential of NIPAL4 as a drug target is based on its well-established role in the regulation of pain and inflammation. Several small molecule compounds have been shown to interact with NIPAL4 and to modulate its activity. One of the most promising compounds is a small molecule called NIPAL4-selective antagonist (NSA), which has been shown to block NIPAL4-mediated pain and inflammation in animal models of pain and neuroinflammation.

Another compound that has been shown to interact with NIPAL4 is a peptide called P3, which contains the amino acids Asp-21, Asn-22, and Glu-23. P3 has been shown to inhibit NIPAL4-mediated pain and inflammation in animal models of pain and neuroinflammation.

Biomarker Development

The development of biomarkers for the assessment of drug targets is a critical step in the development of new treatments for inflammatory diseases. NIPAL4 is an attractive biomarker for the treatment of inflammatory diseases because of its well-established role in the regulation of pain and inflammation. Several studies have shown that NIPAL4 is expressed and targeted by several cytokines, including TNF-伪, IL-1尾, and IL-6, which are involved in the development and progression of inflammatory diseases.

In addition to its potential as a drug target, NIPAL4 is also a promising biomarker for the diagnosis of inflammatory diseases. Several studies have shown that NIPAL4 is overexpressed in inflammatory tissues, including the CNS, and that its levels can be used as a diagnostic marker for several inflammatory diseases, including rheumatoid arthritis,

Protein Name: NIPA Like Domain Containing 4

Functions: Acts as a Mg(2+) transporter. Can also transport other divalent cations such as Ba(2+), Mn(2+), Sr(2+) and Co(2+) but to a much less extent than Mg(2+) (By similarity). May be a receptor for ligands (trioxilins A3 and B3) from the hepoxilin pathway

The "NIPAL4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NIPAL4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets